ProAxsis will be presenting further data on its ProteaseTag® technology, at the North American Cystic Fibrosis Conference, which takes place between November 1st – 5th in Indianapolis. Dr Charlene Robb will be presenting a poster entitled “Do sputum storage conditions impact on the quantification of active neutrophil elastase, interleukin-8, interleukin-6 and tumour necrosis factor-α?” on Thursday November 2nd between 11.15am and 1.45pm (Poster Number 288).
In addition, the team at the Royal Brompton Hospital in London, one of the largest CF expert centres in Europe, will be presenting the first data on the use of the ProteaseTag® Active NE Immunoassay to measure active neutrophil elastase in exhaled breath condensate:
Active Neutrophil Elastase can be detected in Exhaled Breath Condensate in patients with Cystic Fibrosis
C74-ADVANCES IN TRANSLATIONAL COPD
Thematic Poster Session
TUESDAY, MAY 23, 2017
9:15 AM – 4:15 PM
Jane Davies, Professor in Paediatric Respirology & Experimental Medicine at the National Heart and Lung Institute and an Honorary Consultant in Paediatric Respiratory Medicine at the Royal Brompton & Harefield NHS Foundation Trust, said ”To our knowledge this is the first study to report NE in EBC in CF patients; whilst the method requires further optimisation, we believe this could be a promising avenue for monitoring of patients at early stages of disease, such as children.”
Dr David Ribeiro, CEO of ProAxsis, said: “This is the 31st annual NACF Conference, which brings together scientists, clinicians and caregivers from around the world to discuss and share ideas on the latest advances in CF research. The work by Dr Robb and colleagues provides further data for researchers conducting clinical trials worldwide who need to collect, transport and analyse sputum samples for inflammatory biomarkers such as active neutrophil elastase. The 19-patient study conducted at the Royal Brompton Hospital opens up the possibility of utilising the ProAxsis technology for airway monitoring in patients unable to expectorate sputum. We believe these latest findings on our ProteaseTag® technology will be of great interest to the CF community. ”
To find out how ProAxsis can support the measurement of active protease biomarkers of disease, or for any further queries, please contact email@example.com.